NASDAQ$ALEC
Alector Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Alector reported financial results for the third quarter ended September 30, 2020.
Alector reported a net loss of $52.7 million for the quarter ended September 30, 2020, with $461.7 million in cash and investments. Collaboration revenue was $5.9 million, and the company is advancing its clinical programs, including the initiation of a Phase 3 trial for AL001.
- Initiated Phase 3 AL001 trial in people at risk for or with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).
- On track to initiate Phase 2 study for AL002 in Alzheimer’s disease in 2020.
- Collaboration revenue for the quarter ended September 30, 2020, was $5.9 million, compared to $2.7 million for the same period in 2019.
- Cash, cash equivalents, and marketable securities were $461.7 million as of September 30, 2020.
Headline financials
Revenue & EPS history
Alector · Revenue · Quarterly
$5.9M
Revenue by segment
Alector · $5.9M total across 1 segment · Q3 2020
- Collaboration Revenue$5.9M+119.0%100.0%
Forward guidance
Alector believes that its cash and investments as of September 30, 2020, will be sufficient to fund its anticipated operations through 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+1.1%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-5.5%
Avg return
30 days after
52%
15 / 29 earnings
Positive
+32.9%
Q2 2023
Best reaction
-18.4%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.1% | -16.0% | -36.6% | |
| Q4 2025 | +7.1% | -11.7% | -16.3% | |
| Q3 2025 | +4.1% | +8.4% | -2.8% | |
| Q1 2025 | +4.2% | +7.4% | +23.8% | |
| Q4 2024 | -3.5% | -15.4% | -25.0% | |
| Q3 2024 | +12.8% | +21.3% | -56.8% | |
| Q2 2024 | +0.8% | +0.9% | -4.2% | |
| Q1 2024 | -1.9% | +1.7% | -17.7% | |
| Q4 2023 | +7.9% | +14.4% | -7.1% | |
| Q3 2023 | -2.6% | -17.7% | +6.0% | |
| Q2 2023 | +32.9% | +12.4% | -15.6% | |
| Q1 2023 | +13.0% | +20.6% | +8.5% | |
| Q4 2022 | +0.9% | -9.5% | -30.3% | |
| Q3 2022 | -18.4% | +3.1% | +3.1% | |
| Q2 2022 | +16.3% | +12.7% | -6.9% | |
| Q1 2022 | -12.7% | -20.0% | -11.9% | |
| Q4 2021 | +1.9% | -1.3% | -7.8% | |
| Q3 2021 | +2.3% | +4.1% | -20.7% | |
| Q2 2021 | +9.5% | +9.0% | +10.1% | |
| Q1 2021 | -7.8% | -12.4% | +6.1% | |
| Q4 2020 | -4.7% | -10.7% | -14.3% | |
| Q3 2020 | +0.4% | +7.2% | +25.2% | |
| Q2 2020 | -6.9% | -7.4% | -13.5% | |
| Q1 2020 | -5.0% | +0.3% | +3.7% | |
| Q4 2019 | -1.5% | -4.4% | +0.8% | |
| Q3 2019 | -6.1% | -4.2% | +19.5% | |
| Q2 2019 | -1.7% | -18.0% | +9.4% | |
| Q1 2019 | +4.9% | +1.3% | +0.2% | |
| Q4 2018 | -8.6% | -3.5% | +10.8% | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro